bioRxivMolecular BiologyPreprint
Regression from pathological hypertrophy is sexually dimorphic and stimulus-specific
Deanna Muehleman, Alison R. Swearingen, Leslie Anne LeinwandiD
Abstract
AimsPathological cardiac hypertrophy is the result of increased cardiomyocyte size, leading to thickening of the left ventricular walls and a decrease in the left ventricular chamber. With early treatment of the underlying cause, cardiac hypertrophy can be reversed in some individuals, while it persists in others. Here, we investigate mechanisms leading to regression of pathological cardiac hypertrophy in two mouse models, in addition to defining the sex differences associated with hypertrophy and regression.\n\nMethods and ResultsTwo pathological hypertrophic stimuli were used in male and female mice (Isoproterenol or Angiotensin II). The stimulus was removed after 7 days of treatment, then the left ventricle was studied at intervals up to 7 days following the removal of the stimulus. Following Isoproterenol removal, male hearts returned to baseline sizes in 4 days while it took 7 days for female hearts to regress. After Angiotensin II removal, the left ventricular masses of males and females did not regress. ERK1/2 was activated in response to both Isoproterenol and Angiotensin II in males, then decreased back to baseline one day after stimulus removal. Expression of ECM genes was greater in response to Angiotensin II and remained elevated longer after Angiotensin II removal, compared to Isoproterenol. Further, collagen content may be playing a role in the irreversible state of Angiotensin II induced hypertrophy as hydroxyproline content was increased following the removal of Angiotensin II in both males and females.\n\nConclusionsRegression of pathological cardiac hypertrophy is possible in some people and in some mouse models; however, the ability for the heart to regress is dependent on the stimulus and biological sex. Further, molecular changes including cellular signaling, protein degradation pathways and the formation of a fibrotic network may contribute to the ability to reverse pathological cardiac hypertrophy and are stimulus- and sex-dependent.\n\nTranslational PerspectivePathological cardiac hypertrophy is a major risk factor for mortality. If cardiac hypertrophy persists for an extended time, there can be many maladaptive changes to the myocardium. With early treatment of the underlying cause, cardiac hypertrophy can be reversed in some individuals, but not in others. While cardiac hypertrophy has been studied extensively, very little is understood about regression of cardiac hypertrophy. It is important that we have a better understanding of mechanisms leading to regression and why this process might not be reversible in some individuals.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Relative contributions of correcting the diet and voluntary exercise to myocardial recovery in a two-hit murine model of heart failure with preserved ejection fraction.
Emylie-Ann Labbé, Sara-Ève Thibodeau, … Jacques Couët·American Journal of Physiology-Heart and Circulatory PhysiologyPeer-reviewed·May 27, 2025
- Modeling the Interplay of Sex Hormones in Cardiac Hypertrophic Signaling
Adhithi Lakshmikanthan, Minnie Kay, Pim J. A. Oomen·PLoS Computational BiologyPeer-reviewed·Dec 10, 2025
- Striatin plays a major role in angiotensin II-induced cardiomyocyte and cardiac hypertrophy in mice in vivo.
J. J. Cull, S. T. Cooper, … A. Clerk·bioRxiv·Oct 21, 2023
- Contributions of mechanical loading and hormonal changes to eccentric hypertrophy during volume overload: a Bayesian analysis using logic-based network models.
Johane Bracamonte, Lionel D. Watkins, … Jeffrey W. Holmes·PLoS Computational BiologyPeer-reviewed·Apr 16, 2025
- Isoproterenol-induced Cardiac Dysfunction in Male and Female C57Bl/6 Mice
M. K. O. Grant, I. Y. Abdelgawad, … B. Zordoky·bioRxiv·Apr 17, 2020
- Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice
H. O. Alharbi, M. A. Hardyman, … A. Clerk·bioRxiv·Sep 7, 2022